| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammography | 125 | 2021 | 310 | 15.910 |
Why?
|
| Breast Neoplasms | 118 | 2022 | 1536 | 10.410 |
Why?
|
| Radiographic Image Enhancement | 64 | 2018 | 208 | 10.140 |
Why?
|
| Mass Screening | 31 | 2021 | 843 | 3.710 |
Why?
|
| Radiology | 12 | 2019 | 97 | 2.800 |
Why?
|
| Early Detection of Cancer | 11 | 2021 | 454 | 2.740 |
Why?
|
| Breast | 24 | 2021 | 137 | 2.050 |
Why?
|
| X-Ray Diffraction | 8 | 2011 | 53 | 1.960 |
Why?
|
| Sensitivity and Specificity | 60 | 2020 | 1753 | 1.630 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 13 | 2020 | 373 | 1.560 |
Why?
|
| Ultrasonography, Mammary | 12 | 2015 | 39 | 1.320 |
Why?
|
| Female | 143 | 2022 | 38074 | 1.310 |
Why?
|
| Image Processing, Computer-Assisted | 19 | 2007 | 689 | 1.280 |
Why?
|
| Breast Diseases | 14 | 2012 | 40 | 1.240 |
Why?
|
| X-Ray Film | 11 | 2010 | 16 | 1.180 |
Why?
|
| Magnetic Resonance Imaging | 23 | 2018 | 2223 | 1.180 |
Why?
|
| Humans | 167 | 2022 | 68618 | 1.150 |
Why?
|
| Radiology Information Systems | 10 | 2007 | 21 | 1.120 |
Why?
|
| Quality Improvement | 2 | 2021 | 413 | 1.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2012 | 237 | 0.890 |
Why?
|
| Observer Variation | 21 | 2020 | 330 | 0.890 |
Why?
|
| Reproducibility of Results | 28 | 2016 | 2077 | 0.860 |
Why?
|
| Phantoms, Imaging | 16 | 2021 | 189 | 0.840 |
Why?
|
| United States | 32 | 2019 | 7367 | 0.800 |
Why?
|
| Professional Competence | 2 | 2014 | 100 | 0.800 |
Why?
|
| Biopsy, Needle | 9 | 2004 | 191 | 0.790 |
Why?
|
| Radiologists | 1 | 2021 | 35 | 0.770 |
Why?
|
| Data Display | 8 | 2009 | 17 | 0.760 |
Why?
|
| Physician's Role | 2 | 2021 | 116 | 0.760 |
Why?
|
| Estrogens, Conjugated (USP) | 3 | 2017 | 12 | 0.750 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2017 | 38 | 0.740 |
Why?
|
| Middle Aged | 68 | 2018 | 21147 | 0.730 |
Why?
|
| Artificial Intelligence | 4 | 2020 | 159 | 0.720 |
Why?
|
| Breast Density | 3 | 2020 | 21 | 0.680 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2017 | 9 | 0.660 |
Why?
|
| ROC Curve | 12 | 2013 | 392 | 0.620 |
Why?
|
| Calcinosis | 10 | 2012 | 241 | 0.610 |
Why?
|
| Adult | 57 | 2019 | 21403 | 0.610 |
Why?
|
| Aged | 48 | 2017 | 14862 | 0.610 |
Why?
|
| Information Storage and Retrieval | 3 | 2007 | 49 | 0.600 |
Why?
|
| Algorithms | 14 | 2019 | 1196 | 0.580 |
Why?
|
| North Carolina | 16 | 2010 | 224 | 0.560 |
Why?
|
| Carcinoma, Ductal, Breast | 6 | 2010 | 62 | 0.550 |
Why?
|
| Academic Medical Centers | 3 | 2016 | 281 | 0.550 |
Why?
|
| Aged, 80 and over | 22 | 2015 | 4848 | 0.530 |
Why?
|
| Area Under Curve | 7 | 2012 | 238 | 0.520 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2014 | 2324 | 0.500 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 4 | 2010 | 33 | 0.500 |
Why?
|
| Radiography | 1 | 2016 | 572 | 0.490 |
Why?
|
| Biopsy | 17 | 2015 | 540 | 0.490 |
Why?
|
| X-Ray Intensifying Screens | 10 | 2012 | 16 | 0.490 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2015 | 333 | 0.480 |
Why?
|
| Administrative Personnel | 1 | 2014 | 22 | 0.470 |
Why?
|
| False Positive Reactions | 9 | 2015 | 95 | 0.470 |
Why?
|
| Industry | 1 | 2014 | 28 | 0.460 |
Why?
|
| Disclosure | 1 | 2014 | 45 | 0.460 |
Why?
|
| Conflict of Interest | 1 | 2014 | 48 | 0.450 |
Why?
|
| School Admission Criteria | 2 | 2012 | 36 | 0.430 |
Why?
|
| Physicians, Women | 2 | 2016 | 23 | 0.420 |
Why?
|
| Photometry | 1 | 2012 | 6 | 0.420 |
Why?
|
| Predictive Value of Tests | 15 | 2015 | 1465 | 0.410 |
Why?
|
| Carcinoma, Lobular | 4 | 2006 | 20 | 0.400 |
Why?
|
| Pneumonia, Aspiration | 1 | 2011 | 22 | 0.400 |
Why?
|
| Schools, Medical | 2 | 2012 | 157 | 0.390 |
Why?
|
| Radiation Protection | 1 | 2012 | 71 | 0.390 |
Why?
|
| Gastric Acid | 1 | 2011 | 71 | 0.380 |
Why?
|
| Internship and Residency | 5 | 2012 | 596 | 0.370 |
Why?
|
| Time and Motion Studies | 2 | 2010 | 16 | 0.370 |
Why?
|
| Clinical Trials as Topic | 11 | 2015 | 848 | 0.350 |
Why?
|
| Canada | 5 | 2015 | 267 | 0.350 |
Why?
|
| Physical Stimulation | 1 | 2009 | 67 | 0.340 |
Why?
|
| Workflow | 1 | 2010 | 100 | 0.340 |
Why?
|
| Body Burden | 1 | 2009 | 27 | 0.330 |
Why?
|
| Radiotherapy, Conformal | 1 | 2009 | 24 | 0.330 |
Why?
|
| Students, Premedical | 1 | 2008 | 1 | 0.330 |
Why?
|
| Education, Premedical | 1 | 2008 | 3 | 0.330 |
Why?
|
| Mastectomy | 1 | 2009 | 57 | 0.330 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 100 | 0.310 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 201 | 0.310 |
Why?
|
| Bias | 1 | 2009 | 148 | 0.310 |
Why?
|
| Insurance Coverage | 1 | 2008 | 99 | 0.300 |
Why?
|
| Education, Medical | 2 | 2008 | 147 | 0.290 |
Why?
|
| Quality Control | 9 | 2010 | 81 | 0.290 |
Why?
|
| Carcinoma, Medullary | 1 | 2006 | 7 | 0.280 |
Why?
|
| Radiation Dosage | 9 | 2012 | 419 | 0.280 |
Why?
|
| Career Choice | 1 | 2007 | 98 | 0.270 |
Why?
|
| Neoadjuvant Therapy | 4 | 2018 | 104 | 0.270 |
Why?
|
| Patient Compliance | 3 | 1998 | 402 | 0.260 |
Why?
|
| Risk Factors | 18 | 2015 | 5731 | 0.260 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 800 | 0.260 |
Why?
|
| United States Food and Drug Administration | 5 | 2007 | 131 | 0.250 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2006 | 130 | 0.250 |
Why?
|
| Biomarkers, Tumor | 4 | 2016 | 508 | 0.250 |
Why?
|
| Logistic Models | 5 | 2017 | 1420 | 0.250 |
Why?
|
| Follow-Up Studies | 13 | 2015 | 3259 | 0.240 |
Why?
|
| Forecasting | 3 | 2019 | 277 | 0.240 |
Why?
|
| Radiopharmaceuticals | 4 | 2012 | 114 | 0.230 |
Why?
|
| Tomography, Emission-Computed | 2 | 2002 | 40 | 0.230 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 425 | 0.230 |
Why?
|
| Postmenopause | 3 | 2017 | 93 | 0.230 |
Why?
|
| Prevalence | 4 | 2014 | 1619 | 0.230 |
Why?
|
| Equipment Design | 7 | 2009 | 500 | 0.230 |
Why?
|
| Synchrotrons | 3 | 2000 | 7 | 0.220 |
Why?
|
| Histiocytosis, Sinus | 1 | 2003 | 5 | 0.220 |
Why?
|
| Faculty, Medical | 2 | 2016 | 110 | 0.220 |
Why?
|
| Carcinoma | 2 | 2006 | 215 | 0.220 |
Why?
|
| Societies, Medical | 3 | 2006 | 403 | 0.210 |
Why?
|
| Incidence | 6 | 2015 | 1603 | 0.200 |
Why?
|
| Stakeholder Participation | 1 | 2021 | 17 | 0.200 |
Why?
|
| Equipment Failure Analysis | 4 | 2009 | 121 | 0.200 |
Why?
|
| Data Compression | 1 | 2021 | 5 | 0.190 |
Why?
|
| Positron-Emission Tomography | 3 | 2012 | 160 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 767 | 0.190 |
Why?
|
| Internet | 1 | 2004 | 390 | 0.190 |
Why?
|
| Racism | 1 | 2022 | 59 | 0.190 |
Why?
|
| Guideline Adherence | 2 | 2005 | 287 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 468 | 0.180 |
Why?
|
| Attitude of Health Personnel | 3 | 2000 | 442 | 0.180 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2000 | 24 | 0.180 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 33 | 0.180 |
Why?
|
| Crowdsourcing | 1 | 2020 | 8 | 0.180 |
Why?
|
| Computer Simulation | 4 | 2008 | 706 | 0.180 |
Why?
|
| Women's Health | 4 | 2005 | 148 | 0.170 |
Why?
|
| Papilloma, Intraductal | 1 | 1999 | 1 | 0.170 |
Why?
|
| Prospective Studies | 9 | 2018 | 3705 | 0.170 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2019 | 109 | 0.170 |
Why?
|
| Male | 20 | 2019 | 37321 | 0.170 |
Why?
|
| Curriculum | 3 | 2012 | 575 | 0.160 |
Why?
|
| Case-Control Studies | 2 | 2017 | 1553 | 0.160 |
Why?
|
| Health Facilities | 1 | 1998 | 36 | 0.160 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2005 | 75 | 0.160 |
Why?
|
| Registries | 1 | 2021 | 733 | 0.160 |
Why?
|
| Community-Institutional Relations | 1 | 1998 | 59 | 0.150 |
Why?
|
| Machine Learning | 1 | 2019 | 170 | 0.150 |
Why?
|
| Embolization, Therapeutic | 1 | 2000 | 150 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2017 | 127 | 0.150 |
Why?
|
| Rural Health Services | 1 | 1998 | 101 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2014 | 2007 | 0.140 |
Why?
|
| Choline | 1 | 2016 | 14 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2017 | 248 | 0.140 |
Why?
|
| Budd-Chiari Syndrome | 1 | 1996 | 7 | 0.140 |
Why?
|
| Mobile Health Units | 2 | 1995 | 18 | 0.140 |
Why?
|
| Ultrasonography, Doppler | 1 | 1996 | 57 | 0.140 |
Why?
|
| Age Factors | 6 | 2007 | 1864 | 0.140 |
Why?
|
| Leadership | 2 | 2016 | 136 | 0.140 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 1140 | 0.130 |
Why?
|
| Health Personnel | 2 | 1998 | 286 | 0.130 |
Why?
|
| Argentina | 1 | 2015 | 9 | 0.130 |
Why?
|
| Pilot Projects | 7 | 2009 | 1342 | 0.130 |
Why?
|
| Fellowships and Scholarships | 2 | 2012 | 127 | 0.130 |
Why?
|
| Contrast Media | 5 | 2012 | 595 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2019 | 7277 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2016 | 346 | 0.130 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2006 | 100 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2016 | 291 | 0.130 |
Why?
|
| Age Distribution | 4 | 2008 | 320 | 0.130 |
Why?
|
| Surveys and Questionnaires | 6 | 2007 | 2800 | 0.120 |
Why?
|
| Health Care Surveys | 2 | 2007 | 239 | 0.120 |
Why?
|
| Absorptiometry, Photon | 3 | 2006 | 83 | 0.120 |
Why?
|
| Health Behavior | 1 | 1998 | 458 | 0.120 |
Why?
|
| Cats | 1 | 2014 | 292 | 0.120 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2014 | 29 | 0.120 |
Why?
|
| Treatment Outcome | 7 | 2018 | 7029 | 0.120 |
Why?
|
| Organizational Policy | 1 | 2014 | 42 | 0.120 |
Why?
|
| Radiography, Thoracic | 3 | 2011 | 99 | 0.110 |
Why?
|
| Task Performance and Analysis | 3 | 2010 | 150 | 0.110 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2009 | 24 | 0.100 |
Why?
|
| Statistics as Topic | 3 | 2008 | 219 | 0.100 |
Why?
|
| Organizational Objectives | 1 | 2012 | 70 | 0.100 |
Why?
|
| Gadolinium DTPA | 2 | 2006 | 48 | 0.100 |
Why?
|
| Cultural Diversity | 1 | 2012 | 67 | 0.100 |
Why?
|
| Photons | 1 | 2012 | 32 | 0.100 |
Why?
|
| Europe | 1 | 2012 | 196 | 0.100 |
Why?
|
| Self-Examination | 1 | 1991 | 6 | 0.100 |
Why?
|
| Educational Measurement | 2 | 2008 | 254 | 0.090 |
Why?
|
| Endarterectomy, Carotid | 3 | 2001 | 110 | 0.090 |
Why?
|
| Time Factors | 6 | 2010 | 4655 | 0.090 |
Why?
|
| Anxiety | 1 | 2014 | 422 | 0.090 |
Why?
|
| Minority Groups | 1 | 2012 | 197 | 0.090 |
Why?
|
| Calcium, Dietary | 1 | 2010 | 35 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 4 | 2008 | 504 | 0.090 |
Why?
|
| Catheter Ablation | 2 | 2005 | 229 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2010 | 1040 | 0.090 |
Why?
|
| Receptor, ErbB-2 | 2 | 2013 | 129 | 0.090 |
Why?
|
| Decision Making | 1 | 2014 | 410 | 0.090 |
Why?
|
| Patient Care Planning | 1 | 2010 | 108 | 0.090 |
Why?
|
| Neoplasms | 3 | 2008 | 1667 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2009 | 737 | 0.090 |
Why?
|
| Treatment Refusal | 1 | 2010 | 40 | 0.090 |
Why?
|
| Women | 1 | 2010 | 40 | 0.090 |
Why?
|
| United Kingdom | 1 | 2010 | 152 | 0.090 |
Why?
|
| Connective Tissue | 1 | 2009 | 61 | 0.080 |
Why?
|
| Cartilage | 1 | 2009 | 51 | 0.080 |
Why?
|
| Refractometry | 1 | 2009 | 23 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 186 | 0.080 |
Why?
|
| Mastectomy, Segmental | 2 | 2010 | 64 | 0.080 |
Why?
|
| Tendons | 1 | 2009 | 45 | 0.080 |
Why?
|
| Ethics, Research | 1 | 2009 | 12 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 125 | 0.080 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 60 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 50 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2009 | 951 | 0.080 |
Why?
|
| Research | 1 | 2009 | 214 | 0.080 |
Why?
|
| Annual Reports as Topic | 2 | 2007 | 12 | 0.080 |
Why?
|
| Research Personnel | 1 | 2009 | 83 | 0.080 |
Why?
|
| Linear Models | 3 | 2010 | 521 | 0.080 |
Why?
|
| Angiography | 1 | 2009 | 194 | 0.080 |
Why?
|
| Educational Status | 1 | 2008 | 273 | 0.080 |
Why?
|
| Computer Communication Networks | 1 | 2007 | 28 | 0.070 |
Why?
|
| Stereotaxic Techniques | 2 | 2004 | 35 | 0.070 |
Why?
|
| Physical Examination | 3 | 2018 | 152 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2009 | 191 | 0.070 |
Why?
|
| Liquid Crystals | 1 | 2006 | 4 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 369 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2018 | 132 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 2083 | 0.070 |
Why?
|
| Lung | 1 | 2011 | 849 | 0.070 |
Why?
|
| Disease Progression | 1 | 2010 | 1038 | 0.070 |
Why?
|
| Vitamin D | 1 | 2010 | 516 | 0.070 |
Why?
|
| Ultrasonography | 4 | 2012 | 453 | 0.070 |
Why?
|
| Perimenopause | 1 | 2005 | 3 | 0.070 |
Why?
|
| Eye Movements | 2 | 1997 | 44 | 0.070 |
Why?
|
| Quality of Life | 1 | 2014 | 1515 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 1851 | 0.070 |
Why?
|
| Animals | 2 | 2014 | 20881 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 1990 | 581 | 0.070 |
Why?
|
| Models, Theoretical | 2 | 1999 | 384 | 0.070 |
Why?
|
| Premenopause | 1 | 2005 | 57 | 0.060 |
Why?
|
| Computers, Handheld | 1 | 2005 | 44 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2005 | 46 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2009 | 448 | 0.060 |
Why?
|
| Consensus | 1 | 2006 | 211 | 0.060 |
Why?
|
| Telecommunications | 1 | 2005 | 31 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2008 | 310 | 0.060 |
Why?
|
| Culture Techniques | 1 | 2004 | 65 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2012 | 81 | 0.060 |
Why?
|
| Fibrocystic Breast Disease | 2 | 2002 | 7 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2550 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2005 | 2358 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 274 | 0.060 |
Why?
|
| Monte Carlo Method | 1 | 2004 | 124 | 0.060 |
Why?
|
| Adrenal Cortex | 1 | 2003 | 8 | 0.060 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2004 | 52 | 0.060 |
Why?
|
| Carcinoma, Ductal | 1 | 2003 | 14 | 0.060 |
Why?
|
| Rats | 1 | 2011 | 5300 | 0.060 |
Why?
|
| Fibroadenoma | 1 | 2002 | 2 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2004 | 136 | 0.050 |
Why?
|
| Palpation | 2 | 2004 | 21 | 0.050 |
Why?
|
| Nipples | 2 | 1999 | 5 | 0.050 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2001 | 7 | 0.050 |
Why?
|
| Young Adult | 2 | 2012 | 5717 | 0.050 |
Why?
|
| Platelet Adhesiveness | 1 | 2001 | 20 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2003 | 291 | 0.050 |
Why?
|
| Polyesters | 1 | 2001 | 55 | 0.050 |
Why?
|
| Software | 1 | 2004 | 418 | 0.050 |
Why?
|
| Survivors | 1 | 2003 | 256 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2011 | 786 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 168 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 3 | 2007 | 177 | 0.050 |
Why?
|
| Subtraction Technique | 1 | 2000 | 12 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2000 | 48 | 0.050 |
Why?
|
| Teleradiology | 1 | 2000 | 5 | 0.050 |
Why?
|
| Pulmonary Veins | 1 | 2000 | 56 | 0.040 |
Why?
|
| Carotid Stenosis | 2 | 1992 | 163 | 0.040 |
Why?
|
| Device Approval | 1 | 2000 | 6 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 286 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2000 | 119 | 0.040 |
Why?
|
| Normal Distribution | 1 | 1999 | 46 | 0.040 |
Why?
|
| Immersion | 1 | 1999 | 10 | 0.040 |
Why?
|
| Prognosis | 4 | 2006 | 2093 | 0.040 |
Why?
|
| Genes, BRCA2 | 2 | 2011 | 35 | 0.040 |
Why?
|
| Genes, BRCA1 | 2 | 2011 | 47 | 0.040 |
Why?
|
| Solutions | 1 | 1999 | 115 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 1999 | 25 | 0.040 |
Why?
|
| Paget's Disease, Mammary | 1 | 1998 | 4 | 0.040 |
Why?
|
| Light | 1 | 1999 | 152 | 0.040 |
Why?
|
| Connecticut | 1 | 1998 | 13 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2010 | 2279 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 239 | 0.040 |
Why?
|
| Temperature | 1 | 1999 | 341 | 0.040 |
Why?
|
| Atrial Fibrillation | 1 | 2000 | 249 | 0.040 |
Why?
|
| Video Recording | 2 | 1996 | 145 | 0.040 |
Why?
|
| Communication | 1 | 2000 | 329 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 179 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2003 | 703 | 0.040 |
Why?
|
| Computer Terminals | 1 | 1997 | 4 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 1998 | 392 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2003 | 824 | 0.040 |
Why?
|
| Pentetic Acid | 1 | 1996 | 18 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 2010 | 765 | 0.030 |
Why?
|
| Molecular Imaging | 1 | 2016 | 45 | 0.030 |
Why?
|
| Physicians | 1 | 2000 | 324 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 275 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2015 | 4 | 0.030 |
Why?
|
| Carcinoma in Situ | 2 | 2007 | 47 | 0.030 |
Why?
|
| Career Mobility | 1 | 2016 | 34 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 1996 | 95 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2007 | 242 | 0.030 |
Why?
|
| Mentors | 1 | 2016 | 81 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 1996 | 96 | 0.030 |
Why?
|
| Cholecystitis | 1 | 1995 | 12 | 0.030 |
Why?
|
| Attitude to Health | 1 | 1998 | 403 | 0.030 |
Why?
|
| Electric Countershock | 1 | 1996 | 130 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1998 | 300 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 349 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1995 | 59 | 0.030 |
Why?
|
| Acute Disease | 1 | 1996 | 658 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1994 | 73 | 0.030 |
Why?
|
| User-Computer Interface | 2 | 2006 | 230 | 0.030 |
Why?
|
| Computer Systems | 1 | 1994 | 42 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 1994 | 97 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 1173 | 0.030 |
Why?
|
| Femoral Artery | 1 | 1994 | 139 | 0.030 |
Why?
|
| Models, Structural | 1 | 1993 | 22 | 0.030 |
Why?
|
| Television | 1 | 1993 | 28 | 0.030 |
Why?
|
| Health Education | 2 | 1998 | 279 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 57 | 0.030 |
Why?
|
| Computer-Assisted Instruction | 1 | 1993 | 74 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 111 | 0.030 |
Why?
|
| Telephone | 1 | 1993 | 160 | 0.030 |
Why?
|
| Data Collection | 1 | 1994 | 420 | 0.030 |
Why?
|
| Organotechnetium Compounds | 1 | 1992 | 4 | 0.030 |
Why?
|
| Oximes | 1 | 1992 | 10 | 0.030 |
Why?
|
| Rural Population | 1 | 1995 | 398 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 142 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 1266 | 0.030 |
Why?
|
| Government Agencies | 1 | 1992 | 12 | 0.030 |
Why?
|
| Politics | 1 | 1992 | 31 | 0.020 |
Why?
|
| Population Surveillance | 2 | 2007 | 285 | 0.020 |
Why?
|
| Research Design | 2 | 2006 | 729 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1992 | 137 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2011 | 51 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1992 | 172 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 79 | 0.020 |
Why?
|
| Liver | 1 | 1996 | 1118 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1991 | 193 | 0.020 |
Why?
|
| Radionuclide Imaging | 2 | 2001 | 166 | 0.020 |
Why?
|
| New Hampshire | 1 | 2009 | 6 | 0.020 |
Why?
|
| Posture | 1 | 1989 | 107 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 378 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 70 | 0.020 |
Why?
|
| Self Report | 1 | 2010 | 371 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2008 | 58 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 1990 | 383 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 1046 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2008 | 106 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2008 | 122 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 329 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2006 | 23 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 1213 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 1992 | 665 | 0.020 |
Why?
|
| South Carolina | 1 | 2012 | 2752 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2007 | 159 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 74 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 51 | 0.020 |
Why?
|
| Urogenital Neoplasms | 1 | 2005 | 9 | 0.020 |
Why?
|
| Medicare | 1 | 2008 | 319 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 2005 | 10 | 0.020 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2005 | 32 | 0.020 |
Why?
|
| Artifacts | 1 | 2006 | 125 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2005 | 89 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2005 | 40 | 0.020 |
Why?
|
| Telemedicine | 1 | 1993 | 700 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 307 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1994 | 219 | 0.010 |
Why?
|
| Pathology, Clinical | 1 | 2004 | 16 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2006 | 307 | 0.010 |
Why?
|
| Interview, Psychological | 1 | 2003 | 113 | 0.010 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2003 | 4 | 0.010 |
Why?
|
| Reoperation | 2 | 1995 | 467 | 0.010 |
Why?
|
| Vitamin E | 1 | 2003 | 55 | 0.010 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2003 | 150 | 0.010 |
Why?
|
| Pituitary-Adrenal System | 1 | 2003 | 138 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 652 | 0.010 |
Why?
|
| Anticarcinogenic Agents | 1 | 2003 | 52 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2003 | 62 | 0.010 |
Why?
|
| Selenium | 1 | 2003 | 36 | 0.010 |
Why?
|
| Saliva | 1 | 2003 | 142 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 2003 | 218 | 0.010 |
Why?
|
| Lactation | 1 | 2003 | 110 | 0.010 |
Why?
|
| Fear | 1 | 2003 | 239 | 0.010 |
Why?
|
| Affect | 1 | 2003 | 218 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 2001 | 31 | 0.010 |
Why?
|
| Carotid Artery, Common | 1 | 2001 | 25 | 0.010 |
Why?
|
| Suture Techniques | 1 | 2001 | 75 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2006 | 657 | 0.010 |
Why?
|
| Surgical Instruments | 1 | 2001 | 44 | 0.010 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2001 | 54 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2000 | 34 | 0.010 |
Why?
|
| Phlebography | 1 | 2000 | 31 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2003 | 446 | 0.010 |
Why?
|
| Antioxidants | 1 | 2003 | 304 | 0.010 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2000 | 61 | 0.010 |
Why?
|
| Survival Rate | 2 | 1994 | 1056 | 0.010 |
Why?
|
| Adolescent | 2 | 2006 | 8912 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2005 | 561 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 592 | 0.010 |
Why?
|
| Health Care Coalitions | 1 | 1998 | 13 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2000 | 261 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 1998 | 79 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 1997 | 25 | 0.010 |
Why?
|
| Biophysics | 1 | 1997 | 41 | 0.010 |
Why?
|
| X-Rays | 1 | 1997 | 56 | 0.010 |
Why?
|
| Medically Underserved Area | 1 | 1998 | 85 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 2334 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 778 | 0.010 |
Why?
|
| Public Health | 1 | 1998 | 201 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1996 | 160 | 0.010 |
Why?
|
| Biomarkers | 1 | 2001 | 1593 | 0.010 |
Why?
|
| Nurses | 1 | 1996 | 53 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 1995 | 25 | 0.010 |
Why?
|
| Common Bile Duct | 1 | 1995 | 22 | 0.010 |
Why?
|
| Hemoptysis | 1 | 1995 | 28 | 0.010 |
Why?
|
| Videotape Recording | 1 | 1994 | 43 | 0.010 |
Why?
|
| Cough | 1 | 1995 | 65 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 1995 | 129 | 0.010 |
Why?
|
| Pattern Recognition, Visual | 1 | 1994 | 69 | 0.010 |
Why?
|
| Radiography, Abdominal | 1 | 1994 | 57 | 0.010 |
Why?
|
| Health Promotion | 1 | 1998 | 407 | 0.010 |
Why?
|
| Online Systems | 1 | 1993 | 20 | 0.010 |
Why?
|
| Voice | 1 | 1993 | 16 | 0.010 |
Why?
|
| Random Allocation | 1 | 1993 | 442 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 1992 | 9 | 0.010 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 1992 | 12 | 0.010 |
Why?
|
| Carotid Artery, Internal | 1 | 1992 | 85 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1992 | 151 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 1991 | 182 | 0.010 |
Why?
|
| Thrombosis | 1 | 1991 | 218 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1995 | 1615 | 0.000 |
Why?
|
| Smoking | 1 | 1991 | 1452 | 0.000 |
Why?
|